5-[(2,1,3-Benzothiadiazol-5-yl)methylidene]-1,3-thiazolidine-2,4-dione | 648450-68-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻二唑类
• 英文名称: 5-[(2,1,3-Benzothiadiazol-5-yl)methylidene]-1,3-thiazolidine-2,4-dione
• 英文别名: 5-(2,1,3-benzothiadiazol-5-ylmethylidene)-1,3-thiazolidine-2,4-dione
• CAS: 648450-68-4
• 化学式: C₁₀H₅N₃O₂S₂
• 分子量: 263.3
• InChiKey: VFXOODMBCVDUAK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  126
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Azolidinone-vinyl fused-benzene derivatives
  申请人：Rueckle Thomas

  公开号：US20060122176A1

  公开（公告）日：2006-06-08

  The present invention is related to azolidinedione-vinyl fused-benzene derivatives of formula (I) for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, graft rejection or lung injuries. Formula (I), wherein A, X, Y, Z, R 1 , R 2 and n are as described in the description.

  本发明涉及公式（I）的噻唑烷二酮-乙烯基融合苯衍生物，用于治疗和/或预防自身免疫性疾病和/或炎症性疾病、心血管疾病、神经退行性疾病、细菌或病毒感染、肾脏疾病、血小板聚集、癌症、移植排斥或肺损伤。公式（I）中，A，X，Y，Z，R1，R2和n如说明书中所述。
• Use of compounds for increasing spermatozoa motility
  申请人：De Luca Giampiero

  公开号：US20050222225A1

  公开（公告）日：2005-10-06

  The invention relates to a process for the improvement of spermatozoa fertilization activity, in particular for the increase of spermatozoa motility, by using a compound of formula (I). The invention further relates to uses and methods of compounds of formula (I) in infertility and assisted reproduction techniques (ART) as well as to a medium for storage and/or transportation of spermatozoa comprising said P13K inhibitors.

  本发明涉及一种使用式(I)化合物改善精子受精活性的方法，特别是增加精子运动性的方法。本发明还涉及式(I)化合物在不孕症和辅助生殖技术（ART）中的用途和方法，以及一种包含所述P13K抑制剂的精子储存和/或运输介质。
• AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES
  申请人：RUECKLE Thomas

  公开号：US20090306069A1

  公开（公告）日：2009-12-10

  The present invention is related to azolidinedione-vinyl fused-benzene derivatives of formula (I) for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, graft rejection or lung injuries. wherein A, X, Y, Z, R 1 , R 2 and n are as described in the description.

  本发明涉及式（I）的噁唑烷二酮-乙烯基融合苯衍生物，用于治疗和/或预防自身免疫性疾病和/或炎症性疾病、心血管疾病、神经退行性疾病、细菌或病毒感染、肾脏疾病、血小板聚集、癌症、移植排斥或肺损伤。其中A、X、Y、Z、R1、R2和n如描述所述。
• P13K Inhibitors for the Treatment of Endometriosis
  申请人：Palmer Stephen

  公开号：US20080306057A1

  公开（公告）日：2008-12-11

  This invention relates to a method of treating and/or preventing endometriosis comprising administering a PI3K inhibitor. The PI3K inhibitor can also be administered combined with a hormonal suppressor. The invention further relates to the treatment of endometriosis-related infertility.
• P13 kinase gamma inhibitors for the treatment of anaemia
  申请人：Wetzker Reinhard

  公开号：US20090042773A1

  公开（公告）日：2009-02-12

  This present invention is related to the use of selective PD Kinase gamma inhibitors for the manufacture of a medicament for the treatment of disorders related to erythrocyte deficiency. Specifically, the present invention is related to the use of selective PI3 Kinase gamma inhibitors, e.g. substituted azolidinone-vinyl fused-benzene derivatives for the treatment of an anaemia, including haemolytic anaemia, aplastic anaemia and pure red cell anaemia. (I) wherein A, X, Y 1 , Y 2 , Z, n, R 1 and R 2 are described in details in the description hereinafter.